From the Guidelines
Patients on chemotherapy should not receive Paxlovid (nirmatrelvir/ritonavir) without careful consideration by their oncologist and infectious disease specialist due to significant drug interactions. Paxlovid, while effective against COVID-19, contains ritonavir which is a potent inhibitor of CYP3A4, an enzyme that metabolizes many chemotherapy drugs, as noted in recent guidelines 1. This interaction can lead to dangerous increases in chemotherapy drug levels, potentially causing severe toxicity. Some key points to consider in the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation include:
- The use of antivirals such as remdesivir, which has shown benefit in reducing mortality and improving recovery time in cancer patients with COVID-19 2
- The potential benefits and risks of other antiviral treatments, such as molnupiravir and nirmatrelvir-ritonavir combination therapy, which have been supported by recent practice points 1
- The importance of individualized assessment of the specific chemotherapy regimen, cancer type, COVID-19 severity, and the patient's overall clinical status in determining the best course of treatment. As noted in a living WHO guideline on drugs for COVID-19, nirmatrelvir/ritonavir may be a superior choice to other drugs when available and in patients in whom drug interaction is not an issue, but its use in patients on chemotherapy requires careful consideration due to potential drug interactions 3. Alternative COVID-19 treatments such as remdesivir or monoclonal antibodies might be more appropriate options for these patients. The decision to use Paxlovid in patients on chemotherapy should be made on a case-by-case basis, taking into account the potential benefits and risks of treatment, as well as the availability of alternative treatment options.
From the Research
Patient Considerations for Paxlovid Treatment
- Patients undergoing chemotherapy may be at higher risk for severe COVID-19 due to their compromised immune systems 4.
- The use of Paxlovid (nirmatrelvir/ritonavir) in patients with cancer, including those on chemotherapy, has not been extensively studied.
- However, studies have shown that nirmatrelvir/ritonavir can reduce the risk of hospitalization and death in high-risk patients with COVID-19 5, 6.
Safety and Efficacy of Paxlovid
- Nirmatrelvir/ritonavir has been shown to be effective in reducing the risk of hospitalization and death in high-risk patients with COVID-19 5, 6.
- The treatment has been associated with a lower risk of serious adverse events and a similar incidence of adverse events compared to placebo 5, 6.
- However, there is a risk of significant drug-drug interactions with nirmatrelvir/ritonavir, particularly with medications that are highly dependent on CYP3A4 for clearance 7.
Considerations for Patients on Chemotherapy
- Recent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes in one study 4.
- However, patients with active hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes 4.
- The interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation 4.
Current Recommendations
- The use of Paxlovid in patients with cancer, including those on chemotherapy, should be considered on a case-by-case basis, taking into account the individual patient's risk factors and medical history.
- Further studies are needed to fully understand the safety and efficacy of Paxlovid in patients with cancer, including those on chemotherapy 8.